Black Diamond Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
54
- Stock Symbol
-
BDTX
- Share Price
-
$1.59
- (As of Wednesday Closing)
Black Diamond Therapeutics General Information
Description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
Contact Information
Website
www.blackdiamondtherapeutics.comCorporate Office
- One Main Street, PH/14th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- One Main Street, PH/14th Floor
- Cambridge, MA 02142
- United States
Black Diamond Therapeutics Stock Performance
As of 26-Mar-2025, Black Diamond Therapeutics’s stock price is $1.59. Its current market cap is $90.1M with 56.7M shares.
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.59 | $1.69 | $1.57 - $7.66 | $90.1M | 56.7M | 3.26M | -$1.27 |
Black Diamond Therapeutics Financials Summary
As of 31-Dec-2024, Black Diamond Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 31,409 | 31,409 | 26,881 | (49,905) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (71,515) | (71,515) | (83,929) | (92,692) |
| Net Income | (69,676) | (69,676) | (82,442) | (91,169) |
| Total Assets | 122,640 | 122,640 | 158,567 | 156,255 |
| Total Debt | 22,186 | 22,186 | 25,298 | 28,140 |
Black Diamond Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Black Diamond Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Black Diamond Therapeutics Comparisons
Industry
Financing
Details
Black Diamond Therapeutics Competitors (47)
One of Black Diamond Therapeutics’s 47 competitors is Crinetics Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Rhythm Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Black Diamond Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Black Diamond Therapeutics Patents
Black Diamond Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022352658-A1 | Polymorphs as erbb inhibitors | Pending | 21-Sep-2021 | ||
| CA-3231697-A1 | Polymorphs as erbb inhibitors | Pending | 21-Sep-2021 | ||
| EP-4405350-A1 | Polymorphs as erbb inhibitors | Pending | 21-Sep-2021 | ||
| US-20240425492-A1 | Polymorphs as erbb inhibitors | Pending | 21-Sep-2021 | ||
| AU-2022342182-A1 | 6-aza-quinoline derivatives and related uses | Pending | 10-Sep-2021 | A61K31/444 |
Black Diamond Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Black Diamond Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
26.36 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Black Diamond Therapeutics FAQs
-
When was Black Diamond Therapeutics founded?
Black Diamond Therapeutics was founded in 2014.
-
Where is Black Diamond Therapeutics headquartered?
Black Diamond Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Black Diamond Therapeutics?
Black Diamond Therapeutics has 54 total employees.
-
What industry is Black Diamond Therapeutics in?
Black Diamond Therapeutics’s primary industry is Biotechnology.
-
Is Black Diamond Therapeutics a private or public company?
Black Diamond Therapeutics is a Public company.
-
What is Black Diamond Therapeutics’s stock symbol?
The ticker symbol for Black Diamond Therapeutics is BDTX.
-
What is the current stock price of Black Diamond Therapeutics?
As of 26-Mar-2025 the stock price of Black Diamond Therapeutics is $1.59.
-
What is the current market cap of Black Diamond Therapeutics?
The current market capitalization of Black Diamond Therapeutics is $90.1M.
-
Who are Black Diamond Therapeutics’s competitors?
Crinetics Pharmaceuticals, CytomX Therapeutics, Rein Therapeutics, Rhythm Pharmaceuticals, and Arvinas are some of the 47 competitors of Black Diamond Therapeutics.
-
What is Black Diamond Therapeutics’s annual earnings per share (EPS)?
Black Diamond Therapeutics’s EPS for 12 months was -$1.27.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
